Company | Name | Exchange | Sector | Industry | 3 Month | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ABVC Biopharma | NASDAQ | Healthcare | Biotechnology & Medical Research | 318.7% | US$58.18M | -7.9x | -0.23 | US$3.53 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Metaplanet | OTC Markets | 241.9% | US$6.01B | 260.2x | 3.37 | US$9.04 | -2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||||
IREN Ltd | NASDAQ | Technology | Financial Technology (Fintech) & Infrastructure | 222.9% | US$4.37B | -45.5x | 2.07 | US$17.83 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.1% Upside | Upgrade to Pro+ | |
Nuscale Power | NYSE | Utilities | Electrical Utilities & IPPs | 220.5% | US$13.32B | -17x | 0.91 | US$49.97 | 6.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -23.1% Downside | Upgrade to Pro+ | |
D Wave Quantum | NYSE | Technology | Software & IT Services | 199.7% | US$5.80B | -30.8x | 2.65 | US$18.36 | -4.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -6.4% Downside | Upgrade to Pro+ | |
Robinhood Markets | NASDAQ | Technology | Financial Technology (Fintech) & Infrastructure | 156.1% | US$96.88B | 61.4x | 0.05 | US$109.75 | 4.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -2.8% Downside | Upgrade to Pro+ | |
Ast Spacemobile | NASDAQ | Technology | Telecommunications Services | 145.6% | US$19.01B | -30.8x | 0.5 | US$56.47 | -1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -21% Downside | Upgrade to Pro+ | |
Coinbase Global | NASDAQ | Technology | Financial Technology (Fintech) & Infrastructure | 134.7% | US$108.19B | 73.5x | 13.95 | US$424.03 | 3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -26.4% Downside | Upgrade to Pro+ | |
Septerna | NASDAQ | Healthcare | Biotechnology & Medical Research | 113.9% | US$573.02M | -3.3x | 0.06 | US$12.85 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ascentage Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | 111.6% | US$3.36B | -30.1x | -0.97 | US$40.51 | 3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -29.3% Downside | Upgrade to Pro+ | |
ProQR Therapeutics NV | NASDAQ | Healthcare | Biotechnology & Medical Research | 110.5% | US$248.08M | -6.2x | 4.09 | US$2.36 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Phathom Pharma | NASDAQ | Healthcare | Pharmaceuticals | 106.5% | US$585.05M | -1.6x | 0.1 | US$8.43 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
51Talk Online Education DRC | NYSE | Academic & Educational Services | Miscellaneous Educational Service Providers | 97.7% | US$170.63M | -37x | -0.51 | US$29.12 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Futu | NASDAQ | Technology | Financial Technology (Fintech) & Infrastructure | 88.4% | US$22.90B | 26.8x | 0.43 | US$163.69 | 9.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 1.5% Upside | Upgrade to Pro+ | |
Argo Corp | OTC Markets | Technology | Software & IT Services | 84.7% | US$66.63M | -0.07 | US$0.49 | 6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Hims Hers Health | NYSE | Healthcare | Healthcare Providers & Services | 83.6% | US$11.10B | 65.3x | 0.01 | US$49.60 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -9% Downside | Upgrade to Pro+ | |
Critical Metals Corp | NASDAQ | Basic Materials | Metals & Mining | 75.1% | US$451.71M | -1x | US$4.73 | 8.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
CureVac NV | NASDAQ | Healthcare | Biotechnology & Medical Research | 73.1% | US$1.22B | 5.8x | 0.04 | US$5.41 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 0.8% Upside | Upgrade to Pro+ | |
Arrowhead Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | 67.7% | US$2.58B | -16.6x | -0.25 | US$18.58 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Astera Labs | NASDAQ | Technology | Semiconductors & Semiconductor Equipment | 66.1% | US$16.55B | 381.8x | 3.32 | US$100.38 | 2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 2.1% Upside | Upgrade to Pro+ | |
Yuanbao | NASDAQ | 65.7% | US$1.19B | 6.5x | 0.05 | US$27.80 | 5.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||||
Abivax ADR | NASDAQ | Healthcare | Biotechnology & Medical Research | 61.6% | US$641.20M | -0.26 | US$10.03 | -3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Stoke Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | 60.6% | US$775.28M | 15.8x | 0.1 | US$14.25 | 15.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sailfish Royalty | OTC Markets | Basic Materials | Metals & Mining | 58.6% | US$129.78M | 159.9x | 0.88 | US$1.81 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Blueprint Medicines Corp | NASDAQ | Healthcare | Biotechnology & Medical Research | 52.9% | US$8.38B | -52.8x | -1.12 | US$129.46 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -0.4% Downside | Upgrade to Pro+ | |
Himalaya Shipping | NYSE | Industrials | Freight & Logistics Services | 52.1% | US$325.20M | 20.1x | 0.14 | US$6.90 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 26.7% Upside | Upgrade to Pro+ | |
DeFi Tech | NASDAQ | Technology | Financial Technology (Fintech) & Infrastructure | 50.5% | US$1.09B | 55.8x | 0.38 | US$3.31 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Up Fintech | NASDAQ | Financial | Investment Banking & Investment Services | 49.5% | US$1.93B | 22.3x | 0.24 | US$10.88 | 9.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.9% Upside | Upgrade to Pro+ | |
Gold Royalty | NYSE | Financial | Investment Banking & Investment Services | 48.5% | US$411.73M | -123.2x | -1.43 | US$2.41 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24% Upside | Upgrade to Pro+ | |
NYSE | Technology | Software & IT Services | 48.2% | US$26.30B | 232x | 2.13 | US$144.50 | 1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6% Upside | Upgrade to Pro+ | ||
Regenxbio Inc | NASDAQ | Healthcare | Biotechnology & Medical Research | 46.3% | US$425.78M | -2.8x | -0.06 | US$8.43 | -3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Capital Clean Energy | NASDAQ | Industrials | Freight & Logistics Services | 44.9% | US$1.38B | 40.7x | 0.97 | US$23.56 | -3.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -1.8% Downside | Upgrade to Pro+ | |
Dominari Holdings | NASDAQ | Financial | Investment Banking & Investment Services | 40.7% | US$84.13M | -1x | 0.08 | US$5.74 | 2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Elron Electronic Industries | OTC Markets | Financial | Investment Banking & Investment Services | 39.6% | US$81.20M | 4.2x | 0.01 | US$1.54 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Volitionrx Ltd | NYSE | Healthcare | Biotechnology & Medical Research | 38% | US$70.06M | -2.7x | -0.07 | US$0.68 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Avadel Pharma | NASDAQ | Healthcare | Pharmaceuticals | 35% | US$1.05B | -36.6x | -0.47 | US$10.97 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 47.6% Upside | Upgrade to Pro+ | |
Kuros Biosciences | OTC Markets | Healthcare | Biotechnology & Medical Research | 34.9% | US$1.37B | -285.9x | -4.36 | US$36.01 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Mirum Pharmaceuticals | NASDAQ | Healthcare | Pharmaceuticals | 34.9% | US$2.61B | -32.8x | -0.6 | US$52.62 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 37.5% Upside | Upgrade to Pro+ | |
NewAmsterdam Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | 34.5% | US$2.49B | -12.1x | -0.39 | US$22.16 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Cellectis | NASDAQ | Healthcare | Biotechnology & Medical Research | 33.1% | US$133.13M | -3x | -0.04 | US$1.88 | -2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
China Fund | NYSE | Financial | Collective Investments | 32.9% | US$155.46M | 8.1x | US$15.56 | 1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Financial 15 | OTC Markets | Financial | Collective Investments | 32.3% | US$447.82M | 1.7x | US$7.16 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Tetragon | OTC Markets | Financial | Collective Investments | 30.9% | US$1.40B | 4.2x | US$17.15 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Centessa Pharmaceuticals | NASDAQ | Healthcare | Biotechnology & Medical Research | 29.8% | US$2.13B | -7.3x | 0.34 | US$15.69 | -1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ares Commercial RE | NYSE | Real Estate | Residential & Commercial REITs | 29.2% | US$241.93M | -18x | -0.26 | US$4.40 | -2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.9% Upside | Upgrade to Pro+ | |
Finance of America Companies | NYSE | Financial | Investment Banking & Investment Services | 25.9% | US$580.62M | 4.3x | 0.03 | US$23.92 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 3% Upside | Upgrade to Pro+ | |
BeOne Medicines DRC | NASDAQ | Healthcare | Biotechnology & Medical Research | 25.7% | US$34.39B | -68.1x | -1.65 | US$297.43 | 2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.4% Upside | Upgrade to Pro+ | |
SANUWAVE | NASDAQ | Healthcare | Healthcare Equipment & Supplies | 24.8% | US$328.69M | -6.9x | -0.49 | US$38.40 | 2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Dividend 15 Split | OTC Markets | Financial | Investment Banking & Investment Services | 24.8% | US$623.87M | 2x | US$4.61 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Canadian General Investments | OTC Markets | Financial | Collective Investments | 24.5% | US$619.89M | 2.8x | US$29.41 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |